Surgical management of hypertrophic obstructive cardiomyopathy

dc.authorscopusid8515428400
dc.authorscopusid55121114300
dc.authorscopusid58373586900
dc.authorscopusid57210681516
dc.contributor.authorAntal,A.
dc.contributor.authorBoyacıoğlu,K.
dc.contributor.authorAkbulut,M.
dc.contributor.authorAlp,H.M.
dc.date.accessioned2024-05-25T12:33:27Z
dc.date.available2024-05-25T12:33:27Z
dc.date.issued2020
dc.departmentOkan Universityen_US
dc.department-tempAntal A., Clinic of Cardiovascular Surgery, University of Health Sciences, Kartal Kosuyolu Heart Research Center, Istanbul, Turkey; Boyacıoğlu K., Clinic of Cardiovascular Surgery, Bagcılar Research and Training Hospital, Istanbul, Turkey; Akbulut M., Clinic of Cardiovascular Surgery, University of Health Sciences, Kartal Kosuyolu Heart Research Center, Istanbul, Turkey; Alp H.M., Clinic of Cardiovascular Surgery, Okan University Hospital, Istanbul, Turkeyen_US
dc.description.abstractObjective: Septal myectomy is the most effective treatment modality for hypertrophic obstructive cardiomyopathy. A retrospective study was conducted to evaluate outcomes of surgical myectomy alone or with concomitant mitral valve procedures. Methods: From December 2011 through December 2016, a total of 41 patients with symptomatic hypertrophic obstructive cardiomyopathy were operated. There were 14 females and 27 males, aged between 18 and 73 years (mean 49.8 years). All patients had drug refractory symptoms (dyspnea, palpitation, chest pain, fainting, limitation of daily physical activities). Twenty-one patients received septal myectomy alone, 10 patients had SM with mitral valve repair and 10 patients had SM with mitral valve replacement. The average follow-up was 38.45 ± 12.18 months. Results: Surgery led to symptomatic improvement in all patients. None of the patients were left with NYHA Class III and IV symptoms after surgery. The improvement in left ventricular outflow tract gradient was from 116.65 mmHg preoperatively to 22.47 mmHg. Mean septal thickness decreased from 2.35 to 1.74 cm. Post procedure permanent pacemaker implantation was required for one patient due to complete heart block, and 2 intracardiac devices were implanted due to resistant arrthymia. None of the patients required a repeat procedure during follow-up period. Operative mortality was 2.4%. Conclusion: Septal myectomy is safe and effective. Concomitant mitral operations do not increase morbidity and mortality. © 2020, The Japanese Association for Thoracic Surgery.en_US
dc.identifier.citationcount3
dc.identifier.doi10.1007/s11748-020-01306-5
dc.identifier.issn1863-6705
dc.identifier.pmidPubMed:32040818
dc.identifier.scopus2-s2.0-85079461364
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1007/s11748-020-01306-5
dc.identifier.urihttps://hdl.handle.net/20.500.14517/2486
dc.identifier.wosqualityQ4
dc.language.isoen
dc.publisherSpringeren_US
dc.relation.ispartofGeneral Thoracic and Cardiovascular Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHypertrophic obstructive cardiomyopathyen_US
dc.subjectSeptal myectomyen_US
dc.titleSurgical management of hypertrophic obstructive cardiomyopathyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files